BioSpace News Archive

InterVenn Biosciences today announced that Nobel Prize recipient, James P. Allison, has joined the company’s Board of Advisors, effective March 9, 2021. Dr. Allison joins the InterVenn Board of Advisors with over 45 years of experience in Immunology and cancer research.

Mark Christensen, MD, director of emergency medicine at Cullman Regional Medical Center in Cullman, Al., and Highlands Medical Center in Scottsboro, Al., was recently selected as one of five 2020 Facility Medical Directors of the Year by Alteon Health, the industry-leading national medical group that manages these emergency medicine programs.

Michael Silverman, MD, FACEP, chair of emergency medicine at Virginia Hospital Center in Arlington, Va., was recently selected as one of five 2020 Facility Medical Directors of the Year by Alteon Health, the industry-leading national medical group that has managed the hospital’s emergency medicine program since 2001.

Nurses from UC Davis Children’s Hospital, Swedish Edmonds hospital, and Emory Saint Joseph’s Hospital to be recognized at IHI Patient Safety Congress 2021

Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced today its acquisition of A&C, a global GMP (Good Manufacturing Practices) manufacturer of specialty excipients, buffers, and process solutions.

Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced today top-line results from a 400 patient phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ciclesonide metered-dose inhaler in non-hospitalized patients 12 years of age and older with symptomatic COVID-19 infection.

FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD)

Mentice AB, a leading supplier of high-tech solutions for simulation in the medical sector, with a focus on endovascular procedures, announced the appointment of Pontus Appelqvist as Vice President and General Manager for Asia Pacific.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 clinical trial evaluating IDE397 (ClinicalTrials.gov Identifier: NCT04794699)

Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has granted EVRYSDIⓇ (risdiplam) market authorization for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.iii